Markets:

Overview

News

Currencies

International

Treasuries

Alpine Immune Sciences, Inc. - Common Stock (NQ:ALPN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alpine Immune Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

What 11 Analyst Ratings Have To Say About Alpine Immune Sciences ↗

May 16, 2024

Via Benzinga

ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024 ↗

May 09, 2024

ALPN stock results show that Alpine Immune Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Alpine Immune Sciences Reports First Quarter 2024 Financial Results

May 09, 2024

From Alpine Immune Sciences, Inc.

Via Business Wire

3 Growth Stocks You’ll Kick Yourself for Not Buying Today ↗

May 03, 2024

Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns.

Via InvestorPlace

PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 ↗

May 01, 2024

PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.

Via Investor's Business Daily

Alpine Immune Sciences Inc. (NASDAQ: ALPN) is a Stock Spotlight on 4/16

April 16, 2024

Via Investor Brand Network

Sarepta Therapeutics Stock Shows Improved Technical Strength ↗

April 29, 2024

The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.

Via Investor's Business Daily

ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN

April 26, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs ↗

April 26, 2024

Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers.

Via Benzinga

Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy? ↗

April 23, 2024

Vertex is broadening its portfolio.

Via The Motley Fool

Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now ↗

April 22, 2024

These stocks could be near major inflection points.

Via The Motley Fool

3 Relatively Safe Growth Stocks You Can Buy and Hold ↗

April 20, 2024

Low risk and high-reward potential? These stocks could offer both.

Via The Motley Fool

Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy? ↗

April 18, 2024

The biotech just added another potential growth driver to its pipeline.

Via The Motley Fool

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? ↗

April 15, 2024

Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.

Via InvestorPlace

Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock ↗

April 15, 2024

Vertex just laid claim to an asset that might be very valuable.

Via The Motley Fool

Could This Stock Be the Next Biotech Buyout? ↗

April 13, 2024

Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.

Via The Motley Fool

ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN

April 12, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review ↗

April 12, 2024

The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.

Via Investor's Business Daily

Topics Economy

Stocks Surge, Goldgasms To Record High After "Adjusted" PPI Sparks Buying Frenzy ↗

April 11, 2024

What started off as another ugly day with stocks tumbling and yields surging following yesterday's VaR-shock-inducing CPI print, quickly reversed after the market - in its infinite stupidity - took...

Via Talk Markets

Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact ↗

April 11, 2024

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...

Via Benzinga

Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday? ↗

April 11, 2024

Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures...

Via Benzinga

Topics Economy

Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

April 11, 2024

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 11, 2024

Via Benzinga

Alpine Immune Sciences Inc. (NASDAQ: ALPN) Near Top of Volume Charts in Thursday Trading

April 11, 2024

Via Investor Brand Network

Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 11, 2024

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.

Via Benzinga

Topics Stocks

Alpine Immune Sciences Inc. (NASDAQ: ALPN) Records 52-Week High Thursday Morning

April 11, 2024

Via Investor Brand Network

The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today ↗

April 11, 2024

Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.

Via InvestorPlace

Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options ↗

April 11, 2024

Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.

Via Investor's Business Daily

Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune ↗

April 11, 2024

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 11, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.